Objective： To investigate cortactin expression in hepatocellular carcinoma （HCC） and explore its significance in the prognosis of HCC patients. Methods： Immunohistochemistry was performed for paraffin samples of ...Objective： To investigate cortactin expression in hepatocellular carcinoma （HCC） and explore its significance in the prognosis of HCC patients. Methods： Immunohistochemistry was performed for paraffin samples of 119 pairs of HCC tissues （HCCs） and paratumorous liver tissues （PTLTs） to evaluate cortactin expression. The cortactin expression difference in HCCs and PTLTs were analyzed by the McNemar＇s test. The relationship of cortactin expressions in HCCs and clinicopathologic factors was analyzed with Mann-Whitney U test. The Kaplan-Meier method and log-rank test were employed to compare the overall survival between Cortactin negative expression group, weak expression group and strong expression group. Expression of cortactin was further determined in 19 pairs of fresh HCCs and PTLTs specimens with Western blotting. Results： Cortactin expression rate was significantly higher in HCCs （53/119, 44.5%） than that in PTLTs （2/119, 1.7%） （P〈0.001）. The upregulated cortactin expression in HCCs was significantly correlated to absence of capsule formation （P=0.012）, vascular invasion （P=0.037） and high Edmondson-Steiner grade （P=0.020）, and predicted shorter overall survival. Western blotting demonstrated that cortactin expression was upregulated in 9 out of 19 HCCs （47.4%） compared to corresponding PTLTs. Conclusion： Cortactin expression is upregulated in HCC and is related to shorter overall survival of patients, suggesting that cortactin might play roles in the metastasis of HCC and predict a poor prognosis of HCC patients.展开更多
目的:观察肝动脉化疗栓塞(TACE)序贯沙利度胺治疗中晚期肝癌近期疗效,监测治疗前后血清血管内皮生长因子(VEGF)、甲胎蛋白(AFP)变化情况,观察毒副反应。方法:将不能手术切除的中晚期肝癌54例随机分为两组,每组27例。治疗组采用TACE序贯...目的:观察肝动脉化疗栓塞(TACE)序贯沙利度胺治疗中晚期肝癌近期疗效,监测治疗前后血清血管内皮生长因子(VEGF)、甲胎蛋白(AFP)变化情况,观察毒副反应。方法:将不能手术切除的中晚期肝癌54例随机分为两组,每组27例。治疗组采用TACE序贯沙利度胺;对照组单纯行TACE。治疗组沙利度胺100-200mg/d,口服至少3个月。两组患者至少行TACE术2次,于术前及术后4周检测VEGF、AFP水平。结果:治疗组有效率为59.3%,对照组为48.1%,差异无统计学意义(P>0.05);治疗组疾病控制率77.8%,对照组为59.3%,差异有统计学意义(P<0.05);治疗组术后血清VEGF水平较对照组术后显著降低(144.35±70.63ng/L vs 254.35±154.48ng/L),差异有统计学意义(P<0.05);对照组内TACE前后血清VEGF水平比较差异无统计学意义(P>0.05);治疗组术后与对照组术后AFP降低例数比较,治疗组高于对照组(18 vs13),差异有统计学意义(P<0.05);治疗组嗜睡、疲劳、头昏、皮疹等症状较对照组高,两组毒副反应均可耐受。结论:TACE术序贯沙利度胺治疗中晚期肝癌能提高疾病控制率,一定程度上降低血清VEGF、AFP水平,且毒副反应可控,值得进一步研究。展开更多
基金supported by grants from the National"863"High Technology Research and Development Program of China(No.2006AA02A308)the Beijing Municipal Key Project(No.H030230280410)by a grant from the National Key Technologies R&D Program of China(No.2008ZX 10002-016)
文摘Objective： To investigate cortactin expression in hepatocellular carcinoma （HCC） and explore its significance in the prognosis of HCC patients. Methods： Immunohistochemistry was performed for paraffin samples of 119 pairs of HCC tissues （HCCs） and paratumorous liver tissues （PTLTs） to evaluate cortactin expression. The cortactin expression difference in HCCs and PTLTs were analyzed by the McNemar＇s test. The relationship of cortactin expressions in HCCs and clinicopathologic factors was analyzed with Mann-Whitney U test. The Kaplan-Meier method and log-rank test were employed to compare the overall survival between Cortactin negative expression group, weak expression group and strong expression group. Expression of cortactin was further determined in 19 pairs of fresh HCCs and PTLTs specimens with Western blotting. Results： Cortactin expression rate was significantly higher in HCCs （53/119, 44.5%） than that in PTLTs （2/119, 1.7%） （P〈0.001）. The upregulated cortactin expression in HCCs was significantly correlated to absence of capsule formation （P=0.012）, vascular invasion （P=0.037） and high Edmondson-Steiner grade （P=0.020）, and predicted shorter overall survival. Western blotting demonstrated that cortactin expression was upregulated in 9 out of 19 HCCs （47.4%） compared to corresponding PTLTs. Conclusion： Cortactin expression is upregulated in HCC and is related to shorter overall survival of patients, suggesting that cortactin might play roles in the metastasis of HCC and predict a poor prognosis of HCC patients.
文摘目的:观察肝动脉化疗栓塞(TACE)序贯沙利度胺治疗中晚期肝癌近期疗效,监测治疗前后血清血管内皮生长因子(VEGF)、甲胎蛋白(AFP)变化情况,观察毒副反应。方法:将不能手术切除的中晚期肝癌54例随机分为两组,每组27例。治疗组采用TACE序贯沙利度胺;对照组单纯行TACE。治疗组沙利度胺100-200mg/d,口服至少3个月。两组患者至少行TACE术2次,于术前及术后4周检测VEGF、AFP水平。结果:治疗组有效率为59.3%,对照组为48.1%,差异无统计学意义(P>0.05);治疗组疾病控制率77.8%,对照组为59.3%,差异有统计学意义(P<0.05);治疗组术后血清VEGF水平较对照组术后显著降低(144.35±70.63ng/L vs 254.35±154.48ng/L),差异有统计学意义(P<0.05);对照组内TACE前后血清VEGF水平比较差异无统计学意义(P>0.05);治疗组术后与对照组术后AFP降低例数比较,治疗组高于对照组(18 vs13),差异有统计学意义(P<0.05);治疗组嗜睡、疲劳、头昏、皮疹等症状较对照组高,两组毒副反应均可耐受。结论:TACE术序贯沙利度胺治疗中晚期肝癌能提高疾病控制率,一定程度上降低血清VEGF、AFP水平,且毒副反应可控,值得进一步研究。
